Head and Neck Cancers Coverage from Every Angle
Advertisement
Advertisement

Danny Rischin, MD, on Potential New Standards of Care in Head and Neck Squamous Cell Carcinoma

Posted: Monday, June 10, 2019

Danny Rischin, MD, of Peter MacCallum Cancer Centre, discusses the clinical implications of results from KEYNOTE-048, which suggest that pembrolizumab with and without platinum-based chemotherapy plus fluorouracil could be new first-line standards of care for recurrent or metastatic head and neck squamous cell carcinoma.

Advertisement
Advertisement


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.